These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22174792)

  • 1. The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL.
    Plissonnier ML; Fauconnet S; Bittard H; Lascombe I
    PLoS One; 2011; 6(12):e28354. PubMed ID: 22174792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells.
    Plissonnier ML; Fauconnet S; Bittard H; Lascombe I
    Int J Cancer; 2010 Oct; 127(8):1769-84. PubMed ID: 20099277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells.
    Kang DW; Choi CH; Park JY; Kang SK; Kim YK
    Neurochem Res; 2008 Mar; 33(3):551-61. PubMed ID: 17940898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
    Zhang T; Wang X; He D; Jin X; Guo P
    Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.
    Plissonnier ML; Fauconnet S; Bittard H; Mougin C; Rommelaere J; Lascombe I
    Oncotarget; 2017 Dec; 8(64):107744-107762. PubMed ID: 29296202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin.
    Schultze K; Böck B; Eckert A; Oevermann L; Ramacher D; Wiestler O; Roth W
    Apoptosis; 2006 Sep; 11(9):1503-12. PubMed ID: 16820965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.
    Lu M; Kwan T; Yu C; Chen F; Freedman B; Schafer JM; Lee EJ; Jameson JL; Jordan VC; Cryns VL
    J Biol Chem; 2005 Feb; 280(8):6742-51. PubMed ID: 15569667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
    Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
    Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
    Nakata S; Yoshida T; Shiraishi T; Horinaka M; Kouhara J; Wakada M; Sakai T
    Mol Cancer Ther; 2006 Jul; 5(7):1827-35. PubMed ID: 16891469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
    Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo anti-melanoma effects of ciglitazone.
    Botton T; Puissant A; Bahadoran P; Annicotte JS; Fajas L; Ortonne JP; Gozzerino G; Zamoum T; Tartare-Deckert S; Bertolotto C; Ballotti R; Rocchi S
    J Invest Dermatol; 2009 May; 129(5):1208-18. PubMed ID: 19177142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines.
    Strakova N; Ehrmann J; Dzubak P; Bouchal J; Kolar Z
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1239-47. PubMed ID: 14988421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
    Yokoyama Y; Xin B; Shigeto T; Mizunuma H
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The anti-diabetic drug troglitazone sensitizes colon cancer cells to TRAIL-induced apoptosis by down-regulating FLIP].
    Roth W; Grund K; Wiestler OD; Schirmacher P
    Verh Dtsch Ges Pathol; 2007; 91():294-301. PubMed ID: 18314627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
    Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells.
    Kim SH; Yoo CI; Kim HT; Park JY; Kwon CH; Kim YK
    Toxicol Appl Pharmacol; 2006 Sep; 215(2):198-207. PubMed ID: 16616945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin.
    Siegelin MD; Reuss DE; Habel A; Herold-Mende C; von Deimling A
    Mol Cancer Ther; 2008 Nov; 7(11):3566-74. PubMed ID: 19001439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin induces caspase-dependent and caspase-independent apoptosis in human bladder cancer T24 cells.
    Jang JH; Sung EG; Song IH; Lee TJ; Kim JY
    Anticancer Drugs; 2020 Aug; 31(7):655-662. PubMed ID: 32568826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.